Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
101.85
-2.03 (-1.95%)
At close: Nov 20, 2026, 4:00 PM EST
101.94
+0.09 (0.09%)
After-hours: Nov 20, 2026, 7:59 PM EST
Edwards Lifesciences Stock Forecast
Stock Price Forecast
According to 30 analysts polled by S&P Global, Edwards Lifesciences stock has a consensus rating of "Buy" and an average price target of $113.83. The average 1-year stock price forecast is 11.76% higher than the current stock price, while the lowest is $84 (-17.53%) and the highest is $126 (+23.71%).
Price Target: $113.83 (+11.76%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Edwards Lifesciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 18 | 18 | 18 | 18 | 20 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 8 | 7 | 7 | 7 | 7 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 29 | 29 | 30 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $115 | Buy | Reiterates | $115 | +12.91% | Nov 20, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $112 → $116 | Buy | Reiterates | $112 → $116 | +13.89% | Nov 19, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $113 → $121 | Buy | Reiterates | $113 → $121 | +18.80% | Nov 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 9, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $117 → $121 | Buy | Reiterates | $117 → $121 | +18.80% | Nov 9, 2026 |
Financial Forecast
Revenue This Year
6.81B
from 6.07B
Increased by 12.24%
Revenue Next Year
7.48B
from 6.81B
Increased by 9.84%
EPS This Year
3.01
from 2.56
Increased by 17.74%
EPS Next Year
3.40
from 3.01
Increased by 12.95%
EPS and Forward PE are based on non-GAAP adjusted numbers.